Bicara Therapeutics BCAX Business Segments — Total Operating Expenses

Similar metrics at other companies

ARQTReportable Segment — Total Operating Expenses

$114.49M+26.7%

VRDNReportable Segment — Operating Expenses

$116.19M+23.8%

PCVXReportable Segment — Operating Expenses

$345.85M+91.3%

DXPETotal Reportable Segments — Operating Expenses

$440.04M+8.0%

CASYReportable Segment — Operating Expenses

$730.02M+10.1%

SLMReportable Segment — Operating Expenses

$170.36M+10.9%

Questions, answered.

What is Bicara Therapeutics's business segments — total operating expenses?

Bicara Therapeutics (BCAX) reported business segments — total operating expenses of $60.24M in Q1 2026.

How has Bicara Therapeutics's business segments — total operating expenses changed year-over-year?

Bicara Therapeutics's business segments — total operating expenses increased by 44.2% year-over-year, from $41.79M to $60.24M.

What is the long-term trend for Bicara Therapeutics's business segments — total operating expenses?

Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — total operating expenses has grown at a 97.5% compound annual growth rate (CAGR), from $39.89M to $155.6M.

What does business segments — total operating expenses mean?

The sum of all costs incurred in the normal course of business, including research and development, clinical operations, and general administrative overhead. This metric is a key indicator of the company's total cash burn rate and operational scale.